Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.60 Average Target Price from Analysts

Gossamer Bio, Inc. (NASDAQ:GOSS) has earned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $8.60.

GOSS has been the subject of several recent research reports. Barclays initiated coverage on Gossamer Bio in a report on Tuesday, January 27th. They set an “overweight” rating and a $9.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a research note on Thursday, January 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of GOSS. Walleye Capital LLC boosted its position in shares of Gossamer Bio by 97.4% during the fourth quarter. Walleye Capital LLC now owns 1,077,032 shares of the company’s stock valued at $3,339,000 after buying an additional 531,353 shares during the last quarter. Hudson Bay Capital Management LP purchased a new position in Gossamer Bio during the 4th quarter worth $44,000. Jacobs Levy Equity Management Inc. boosted its holdings in Gossamer Bio by 54.7% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 2,178,033 shares of the company’s stock worth $6,752,000 after acquiring an additional 769,915 shares during the last quarter. Rafferty Asset Management LLC bought a new stake in shares of Gossamer Bio in the 4th quarter worth $970,000. Finally, State Street Corp lifted its position in shares of Gossamer Bio by 139.7% during the fourth quarter. State Street Corp now owns 9,310,969 shares of the company’s stock valued at $28,864,000 after purchasing an additional 5,427,302 shares in the last quarter. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Price Performance

Shares of Gossamer Bio stock opened at $2.29 on Friday. The business has a 50-day simple moving average of $2.86 and a 200 day simple moving average of $2.67. Gossamer Bio has a one year low of $0.76 and a one year high of $3.87. The firm has a market capitalization of $530.04 million, a price-to-earnings ratio of -3.32 and a beta of 1.93.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.